CASCADE Conformal Prediction: Uncertainty-Adaptive Prediction Intervals for Two-Stage Clinical Decision Support
Ricardo Diaz-Rincon, Muxuan Liang, Adolfo Ramirez-Zamora, Benjamin Shickel · 2026
Read CASCADE Conformal Prediction: Uncertainty-Adaptive Prediction Intervals for Two-Stage Clinical Decision Support by Ricardo Diaz-Rincon, Muxuan Liang, Adolfo Ramirez-Zamora, Benjamin Shickel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2605-20468.txt.
Introduction
Diaz-Rincon and three co-workers give Parkinson's dose forecasts bands that widen or narrow with confidence. Standard conformal bands treat sure and shaky calls alike, hiding how much a levodopa dose forecast can be trusted. Their CASCADE framework scales intervals for a two-stage decision: first whether a dose change is needed, then how much change. Patients the model trusts get intervals 38.9 percent narrower than standard baselines, while uncertain cases widen to hold coverage.
Catalog record
| CREATOR | Ricardo Diaz-Rincon, Muxuan Liang, Adolfo Ramirez-Zamora, Benjamin Shickel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47085 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2605.20468
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
CASCADE Conformal Prediction: Uncertainty-Adaptive Prediction Intervals for Two-Stage Clinical Decision Support Ricardo Diaz-Rincon, Muxuan Liang, Adolfo Ramirez-Zamora, Benjamin Shickel Abstract Effective medication management in Parkinson’s Disease (PD) is challenging due to heterogeneous disease progression, variable patient response, and medication side effects. While AI models can forecast levodopa equivalent daily dose (LEDD) as a measure of medication needs, standard uncertainty quantification often fails to communicate the reliability of these predictions, treating high and low confidence clinical decisions identically. We introduce CASCADE (Calibrated Adaptive Scaling via Conformal And Distributional Estimation), a novel conformal prediction framework that propagates epistemic uncertainty from a screening classifier to adapt downstream predictions. Unlike standard conformal methods that rely on auxiliary residual regression, we leverage epistemic uncertainty from a primary classification task (identifying whether a medication change is needed) to dynamically scale the prediction intervals of a secondary regression task (predicting how much change). By mapping Venn-Abers multi-probabilistic uncertainty directly to non-conformity scores, our framework achieves continuous risk adaptation. We demonstrate that this “cascade effect” produces highly efficient intervals for confident patients (38.9% narrower than standard conformal baselines) while automatically expanding intervals to ensure robust coverage for uncertain cases, bridging the gap between discrete clinical decision-making and continuous dose forecasting in PD. 1 Introduction Figure 1 : Overview of the CASCADE Framework. (a) Two-Stage Architecture: A Stage 1 classifier identifies patients requiring medication adjustment, followed by a Stage 2 regressor that predicts the dosage. (b) Uncertainty Quantification: CASCADE extracts the epistemic uncertainty score u_{\text{VA}}(x) directly from the Stage 1 predicted probability \hat{p}(x) . This score flows into the scaling function \sigma(x) (highlighted in red), which scales the prediction interval. This mathematical propagation drives the “cascade effect” (red dashed arrow), where the final adaptive interval \hat{C}(x) expands or shrinks based on patient uncertainty. Parkinson’s Disease (PD) medication management is a high-stakes sequential decision problem: first determining whether a dosage adjustment is needed, then quantifying how much. Dosing errors carry direct patient risk: inadequate titration leaves patients with debilitating motor symptoms, while over-medication can trigger levodopa-induced dyskinesia (LID) and neuropsychiatric complications ( 3 ; 12 ) . The levodopa equivalent daily dose (LEDD) standardizes medication burden across drug classes ( 29 ) , but optimal titration remains a subjective, trial-and-error process heavily reliant on brief clinical assessments ( 3 ) . Recent advancements in artificial intelligence (AI) have accelerated the adoption of clinical decision support systems. Because most clinical decisions follow a hierarchical logic: first determining if an intervention is needed before deciding how much , these systems increasingly rely on two-stage architectures. In PD, such a system operates in two stages: first, a classifier identifies if a patient’s medication regimen requires adjustment; second, a regression model predicts how much the dosage should change ( 8 ) . However, applying uncertainty quantification to these two-stage architectures presents a critical challenge: information loss at the decision boundary. While conformal prediction (CP) provides distribution-free coverage guarantees for such models ( 30 ; 25 ) , it typically treats the regression stage in isolation, regardless of first-stage uncertainty. Consider a neurologist using such a system for two patients: For patient A, the system is 99% certain a medication change is needed. For patient B, the system is ambivalent, predicting a change with 55% certainty (hovering near the 0.5 decision boundary). A standard regression model, blind to this upstream wavering, treats these two patients identically, resulting in static conservatism. It might predict a 20% medication increase for both, assigning similar confidence intervals. However, the clinical risk profile is vastly different: the prediction for patient A is actionable, while the prediction for patient B is uncertain, carrying a higher risk of errors that could potentially lead to levodopa-induced dyskinesia ( 12 ; 20 ; 14 ) and other complications ( 18 ; 28 ) . This scenario, illustrated in Figure 2 (a), exposes a critical gap that limits the adoption of uncertainty quantification in high-stakes healthcare settings. To bridge this gap, we introduce CASCADE (Calibrated Adaptive Scaling via Conformal And Distributional Estimation), a framework that explicitly couples classification uncertainty with regression calibration. Instead of treating these stages independently, we propose that the epistemic uncertainty of the Stage 1 decision, measured through Venn-Abers (VA) predictors ( 31 ) , should serve as a dynamic scaling factor for the Stage 2 prediction intervals. This creates a “cascade effect”: as the system’s uncertainty increases, the prediction intervals automatically widen to reflect this. Clinically, this ensures that the model’s reliability scales with the difficulty of the case, acting as a safeguard by preventing dangerous overconfidence in complex scenarios while maintaining high precision for straightforward patients. Our contributions. (1) We introduce the CASCADE framework, creating a mechanism to map Venn-Abers uncertainty directly to conformal non-conformity scores. This enables cross-task uncertainty transfer, leveraging classification reliability to scale regression intervals without the computational overhead of training auxiliary error models. (2) We implement CASCADE using two distinct strategies: a discrete Mondrian approach and a Continuous Cascade approach using mean-centered scaling. Within the continuous implementation we introduce a tunable scaling parameter ( {\beta} ), allowing practitioners to explicitly calibrate the system’s sensitivity to uncertainty. We demonstrate that this continuous parameterization removes the discretization artifacts and sample-size fragmentation inherent in traditional binning approaches. (3) We validate this approach on a decade of PD inpatient data from 631 patients at the University of Florida (UF) Health, showing that CASCADE maintains marginal coverage guarantees while reducing interval length by 38.9% for high-confidence patients compared to baselines. 2 Related Work Figure 2 : The CASCADE Mechanism. (a) Standard System: The regression model is blind to upstream confidence, producing non-informative, fixed-length prediction intervals for both the low uncertainty Patient A ( p=0.99 ) and the high uncertainty (ambiguous) Patient B ( p=0.55 ). While actionable for A, this rigidity is dangerous for B: the model confidently predicts a dosage increase despite high ambiguity. This erroneous precision carries a high risk of over-medication, potentially driving the patient into the levodopa-induced dyskinesia “(LID) Risk Zone”. (b) CASCADE (Proposed): The framework solves this by explicitly coupling the two stages, translating the epistemic uncertainty from Stage 1 into Stage 2. Left (Patient A): High confidence results in a minimal Venn-Abers score ( u_{\text{VA}} ). The mechanism responds with compressive scaling, producing an optimized prediction, eliminating unnecessary conservatism and confirming the dosage target is safe. Right (Patient B): The increased uncertainty yields a high ( u_{\text{VA}} ). The mechanism responds with expansive scaling, creating an adaptive safety buffer that covers the ground truth and explicitly signals that a standard dosage increase carries significant risk. Machine Learning in PD Medication Management. To facilitate medication decisions, recent approaches have applied machine learning to forecast medication needs through the LEDD ( 7 ) . These range from predicting raw levodopa doses ( 24 ) and post-surgical adjustments ( 26 ) to clustering medication regimes ( 32 ) and optimizing combinations via reinforcement learning ( 16 ) . While these approaches achieve adequate accuracy, they predominantly rely on point predictions without accounting for prediction uncertainty. In high-stakes clinical settings, a single deterministic value without reliability bounds is insufficient, as it fails to distinguish between a robust forecast and a statistical guess. Without uncertainty bounds, models may encourage overconfident